Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARB-001467 combination study in HBeAg-negative chronic hepatitis B
2017-001647-12Phase 2Terminated
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Oct 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARB-1467 in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Primary endpoint: Proportion of treated subjects with HBsAg decline >=2 log10. Started Oct 2017; status: terminated.
02
Drugs
ARB-1467
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2017-001647-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001647-12.